DOPAR
LOE ApproachingNDAORALTABLET
Approved
Jun 1970
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
2/8 — Basic
Drug data last refreshed 12h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DOPAR is an oral small-molecule tablet approved in 1970 for an unknown indication under Takeda sponsorship. The mechanism of action and therapeutic class are not documented in available data. Patient population and clinical use cannot be determined without indication information.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100); expect downsizing or transition team focus to generic defense strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Efficacy and Safety of Entacapone Combined With Madopar in the Treatment of Early Parkinson's Disease: An Observational, Multicenter, Case-Control Study
Started Jun 2025
216 enrolled
Parkinson Disease (PD)
Assess Efficacy and Safety of the Dopamine Agonist Pramipexole Versus Levodopa / Benserazide (Madopar® DR) in Patients With Restless Legs Syndrome
Started Feb 2003
58 enrolled
Restless Legs Syndrome
Career Relevance
Zero linked job openings suggest limited current hiring for DOPAR-specific roles. Career growth on this product is constrained by its LOE-approaching lifecycle and mature market position, making it a defensive rather than growth opportunity.
Worked on DOPAR at Takeda? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.